Page 60 - Read Online

Page 10 of 14 Stenina-Adognravi et al. Vessel Plus 2018;2:30 I http://dx.doi.org/10.20517/2574-1209.2018.40

32. Muppala S, Frolova E, Xiao R, Krukovets I, Yoon S, et al. Proangiogenic properties of thrombospondin-4. Arterioscler Thromb Vasc
Biol 2015;35:1975-86.
33. Muppala S, Xiao R, Krukovets I, Verbovetsky D, Yendamuri R, et al. Thrombospondin-4 mediates TGF-β-induced angiogenesis. Onco-
gene 2017;36:5189-98.
34. Pluskota E, Stenina OI, Krukovets I, Szpak D, Topol EJ, et al. Mechanism and effect of thrombospondin-4 polymorphisms on neutro-
phil function. Blood 2005;106:3970-8.
35. Frolova EG, Pluskota E, Krukovets I, Burke T, Drumm C, et al. Thrombospondin-4 regulates vascular inflammation and atherogenesis.
Circ Res 2010;107:1313-25.
36. Frolova EG, Sopko N, Blech L, Popovic ZB, Li J, et al. Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in re-
sponse to pressure overload. FASEB J 2012;26:2363-73.
37. Greco SA, Chia J, Inglis KJ, Cozzi SJ, Ramsnes I, et al. Thrombospondin-4 is a putative tumour-suppressor gene in colorectal cancer
that exhibits age-related methylation. BMC Cancer 2010;10:494.
38. van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, et al. Epigenetic profiling of cutaneous T-cell lymphoma:
promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005;23:3886-96.
39. Adams JC, Monk R, Taylor AL, Ozbek S, Fascetti N, et al. Characterisation of drosophila thrombospondin defines an early origin of
pentameric thrombospondins. J Mol Biol 2003;328:479-94.
40. Stenina-Adognravi O. Thrombospondins: old players, new games. Curr Opin Lipidol 2013;24:401-9.
41. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2
independent regions within the type 1 repeats. Circulation 1999;100:1423-31.
42. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002;6:1-12.
43. Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J
Biol Chem 2000;275:32167-73.
44. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, et al. Thrombospondin-1 suppresses spontaneous tumor growth
and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A
2001;98:12485-90.
45. Murphy-Ullrich JE, Schultz-Cherry S, Höök M. Transforming growth factor-beta complexes with thrombospondin. Mol Biol Cell
1992;3:181-8.
46. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, et al. Regulation of transforming growth factor-beta activation
by discrete sequences of thrombospondin 1. J Biol Chem 1995;270:7304-10.
47. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, et al. Thrombospondin-1 is a major activator of TGF-beta1 in
vivo. Cell 1998;93:1159-70.
48. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immu-
nologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990;87:6624-8.
49. Ichii T, Koyama H, Tanaka S, Shioi A, Okuno Y, Otani S, et al. Thrombospondin-1 mediates smooth muscle cell proliferation induced
by interaction with human platelets. Arterioscler Thromb Vasc Biol 2002;22:1286-92.
50. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, et al. CD36 mediates the in vitro inhibitory effects of thrombospondin-1
on endothelial cells. J Cell Biol 1997;138:707-17.
51. Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce
apoptosis of endothelial cells. Cancer Res 1997;57:1735-42.
52. Vogel T, Guo NH, Krutzsch HC, Blake DA, Hartman J, et al. Modulation of endothelial cell proliferation, adhesion, and motility by re-
combinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem 1993;53:74-84.
53. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 2000;12:634-40.
54. Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci 2008;65:700-12.
55. Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004;36:1038-45.
56. Gutierrez LS, Suckow M, Lawler J, Ploplis VA, Castellino FJ. Thrombospondin 1--a regulator of adenoma growth and carcinoma
progression in the APC(Min/+) mouse model. Carcinogenesis 2003;24:199-207.
57. Almog N, Henke V, Flores L, Hlatky L, Kung AL, et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor
angiogenesis. FASEB J 2006;20:947-9.
58. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, et al. A model of human tumor dormancy: an angiogenic switch from the
nonangiogenic phenotype. J Natl Cancer Inst 2006;98:316-25.
59. Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, et al. Sustained regression of tumors upon MYC inactivation requires p53 or
thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A 2006;103:16266-71.
60. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, et al. Transfection of thrombospondin 1 complemen-
tary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res
1994;54:6504-11.
61. Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and
angiogenesis. Proc Natl Acad Sci U S A 1999;96:14888-93.
62. Streit M, Velasco P, Brown LF, Skobe M, Richard L, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the
growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999;155:441-52.
63. Sheibani N, Frazier WA. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses